Avidity Biosciences recently joined PPMD for a community webinar to share topline data from their EXPLORE44® clinical trial, which is assessing the safety and efficacy of the investigational therapy delpacibart zotadirsen (formerly AOC 1044, abbreviated as del-zota) in people living with Duchenne mutations amenable to exon 44 skipping. The Avidity team shared background information about del-zota and the EXPLORE44 study, provided an overview of results, and answered questions from the community.
- Catégories
- Webinar
Commentaires